HUDDINGE, Sweden, April 23, 2004 (PRIMEZONE) -- Karo Bio:
-- Substantial progress has been made in the collaboration with Wyeth
Pharmaceuticals in the discovery of lead compounds that show
significant anti atherogenic effects in animal disease models.
-- The internal STAD dyslipidemia project continues to make good progress
and two patent applications have been filed for selected compounds.
-- New and more potent androgen antagonists have been designed in the
prostate cancer project and a patent application has been filed for
selected compounds.
-- Net sales amounted to MSEK 10.1 (12.7).
-- The loss for the period, including goodwill expenses, decreased to
MSEK 34.2 (100.4). Operating loss excluding goodwill expenses
decreased to MSEK 35.1 (42.0).
-- Cash flows from operating activities amounted to MSEK -36.1 (-39.7).
Cash and cash equivalents and short-term investments amounted to
MSEK 148.9 (161.2) at the end of the period.
-- Loss per share for the period amounted to SEK 2.03 (7.82).
This information was brought to you by Waymaker http://www.waymaker.net
The full report is available for download:
http://www.waymaker.net/bitonline/2004/04/23/20040423BIT00020/wkr0001.doc
http://www.waymaker.net/bitonline/2004/04/23/20040423BIT00020/wkr0002.pdf